Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses
暂无分享,去创建一个
Dinler A. Antunes | Roland Jacobs | M. Manns | D. Antunes | C. Klade | R. Jacobs | H. Wedemeyer | M. Cornberg | Heiner Wedemeyer | Michael P. Manns | G. Vieira | Markus Cornberg | Shihong Zhang | Gustavo F. Vieira | Verena Schlaphoff | Paraskevi Fytili | Rakesh K. Bakshi | Pothakamuri Venkata Suneetha | Christoph S. Klade | Anke R. M. Kraft | Shihong Zhang | P. Suneetha | V. Schlaphoff | R. Bakshi | P. Fytili | A. Kraft | Rakesh K Bakshi
[1] Y. Naumov,et al. Memory of mice and men: CD8+ T‐cell cross‐reactivity and heterologous immunity , 2006, Immunological reviews.
[2] F. Celada,et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. , 2006, The Journal of clinical investigation.
[3] Henrique Veiga-Fernandes,et al. Response of naïve and memory CD8+ T cells to antigen stimulation in vivo , 2000, Nature Immunology.
[4] R. Fujinami,et al. Pathogenic epitopes, heterologous immunity and vaccine design , 2007, Nature Reviews Microbiology.
[5] J. Ghrayeb,et al. Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.
[6] E. Gostick,et al. Immunodominance of HLA-A2-Restricted Hepatitis C Virus-Specific CD8+ T Cell Responses Is Linked to Naïve-Precursor Frequency , 2011, Journal of Virology.
[7] Mario Roederer,et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial , 2015, The Lancet.
[8] Marialva Sinigaglia,et al. Structural in silico analysis of cross-genotype-reactivity among naturally occurring HCV NS3-1073-variants in the context of HLA-A*02:01 allele. , 2011, Molecular immunology.
[9] C. Klade,et al. Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. , 2010, Vaccine.
[10] C. Klade,et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. , 2006, Vaccine.
[11] A. Bertoletti,et al. Heterologous T cell immunity in severe hepatitis C virus infection , 2005, The Journal of experimental medicine.
[12] R. Welsh,et al. Private specificities of CD8 T cell responses control patterns of heterologous immunity , 2005, The Journal of experimental medicine.
[13] L. Kane. Faculty Opinions recommendation of Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. , 2013 .
[14] M. Manns,et al. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. , 2008, Vaccine.
[15] Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections , 2014, Medical Microbiology and Immunology.
[16] F. Chisari,et al. Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.
[17] M. Jenkins,et al. The Role of Naive T Cell Precursor Frequency and Recruitment in Dictating Immune Response Magnitude , 2012, The Journal of Immunology.
[18] A Sette,et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. , 1999, Journal of immunology.
[19] B. Korber,et al. Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors , 2014, The Journal of experimental medicine.
[20] D. Douek,et al. Unbiased Molecular Analysis of T Cell Receptor Expression Using Template‐Switch Anchored RT‐PCR , 2011, Current protocols in immunology.
[21] M. Albert,et al. Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. , 2010, Blood.
[22] G. Nolan,et al. Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes , 2014, The Journal of Immunology.
[23] J. Bennink,et al. Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells , 2001, Journal of Virology.
[24] Raymond M. Welsh,et al. No one is naive: the significance of heterologous T-cell immunity , 2002, Nature Reviews Immunology.
[25] B. Walker,et al. Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. , 2008, The Journal of clinical investigation.
[26] Atul J. Butte,et al. Variation in the Human Immune System Is Largely Driven by Non-Heritable Influences , 2015, Cell.
[27] S. Jameson,et al. Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. , 2013, Immunity.
[28] G. Rimmelzwaan,et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. , 2014, The Lancet. Infectious diseases.
[29] M. Manns,et al. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response , 2007, Virology Journal.
[30] Mark M. Davis,et al. Deconstructing the Peptide-MHC Specificity of T Cell Recognition , 2014, Cell.
[31] P. Doherty,et al. Protective Efficacy of Cross-Reactive CD8+ T Cells Recognising Mutant Viral Epitopes Depends on Peptide-MHC-I Structural Interactions and T Cell Activation Threshold , 2010, PLoS pathogens.
[32] Mark M. Davis,et al. Antiviral memory phenotype T cells in unexposed adults , 2013, Immunological reviews.
[33] Mark M Davis,et al. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. , 2013, Immunity.
[34] Yan Zhou,et al. Will There Be a Vaccine to Prevent HCV Infection? , 2014, Seminars in Liver Disease.
[35] Todd M. Allen,et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.
[36] F. Heinemann,et al. Impact of Sequence Variation in a Dominant HLA-A*02-Restricted Epitope in Hepatitis C Virus on Priming and Cross-Reactivity of CD8+ T Cells , 2014, Journal of Virology.
[37] M. Bonneville,et al. Selection of high‐avidity CD8 T cells correlates with control of hepatitis C virus infection , 2008, Hepatology.
[38] J. Sidney,et al. Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection , 2012, The Journal of Immunology.
[39] R. Welsh. Private specificities of heterologous immunity. , 2006, Current opinion in immunology.
[40] Mark M. Davis,et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.
[41] D. D. Des Jarlais,et al. Hepatitis C virus‐specific T‐cell immune responses in seronegative injection drug users , 2009, Journal of viral hepatitis.
[42] L. Watkin,et al. CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections , 2010, The Journal of Immunology.
[43] Marialva Sinigaglia,et al. CrossTope: a curate repository of 3D structures of immunogenic peptide: MHC complexes , 2013, Database J. Biol. Databases Curation.
[44] B. Walker,et al. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. , 1997, The Journal of infectious diseases.
[45] A. Folgori,et al. Cross‐reactivity of hepatitis C virus specific vaccine‐induced T cells at immunodominant epitopes , 2014, European journal of immunology.